Recurrent chalazia secondary to bortezomib
Few cases of chalazia secondary to bortezomib are reported in literature. However, it is not a recognized ocular adverse effect. We hereby report a case of recurrent chalazia secondary to bortezomib. A 40-year-old male with light chain myeloma on ten weeks of chemotherapy with bortezomib was t...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Pusat Perubatan Universiti Kebangsaan Malaysia
2018
|
| Online Access: | http://journalarticle.ukm.my/20625/1/24_ms419_pdf_83654.pdf http://journalarticle.ukm.my/20625/ https://www.medicineandhealthukm.com/toc/13/2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universiti Kebangsaan Malaysia |
| Language: | English |
| Summary: | Few cases of chalazia secondary to bortezomib are reported in literature. However,
it is not a recognized ocular adverse effect. We hereby report a case of recurrent
chalazia secondary to bortezomib. A 40-year-old male with light chain myeloma
on ten weeks of chemotherapy with bortezomib was treated for left eye inflamed
chalazion with bilateral meibominitis. Severe chalazia persisted despite treatment,
which necessitated cessation of chemotherapy. The patient’s condition improved on
oral doxycycline and chemotherapy was recommenced but his chalazia recurred,
necessitating incision and curretage. His chalazia responded to oral azithromycin
without further cessation of chemotherapy. Bortezomib’s association with chalazia
has been characterized as a possible adverse drug reaction according to the World
Health organization classification, and its recognization as an established adverse
reaction to will allow earlier identification and appropriate co-management of the
patient. |
|---|